期刊
JOURNAL OF INTERNAL MEDICINE
卷 291, 期 6, 页码 877-885出版社
WILEY
DOI: 10.1111/joim.13462
关键词
anticoagulants; apixaban; extended phase anticoagulation; major bleeding; venous thromboembolism
资金
- BMS/Pfizer Alliance American Thrombosis Investigator Initiated Research Program (ARISTA-USA)
This study provides evidence that apixaban 2.5 mg twice daily is an alternative option for extended phase therapy for risk reduction of VTE recurrence compared to apixaban 5 mg twice daily.
Background The optimal dose of apixaban therapy to prevent asecondary venous thromboembolism (VTE) event remains unconfirmed. To investigate the effects of extended phase use of apixaban (2.5 vs. 5 mg twice daily) beyond 6 months of initial treatment on the risk of recurrent VTE and major bleeding events among patients with a history of VTE. Methods A retrospective cohort analysis of two large national insurance claims databases was conducted for patients diagnosed with VTE. Cox proportional hazard models after propensity score matching were used to compare the risk of recurrent VTE and major bleeding. Results There were no detected differences in recurrent VTE or major bleeding events between patients prescribed low versus full dose apixaban. Conclusion This study provides evidence that apixaban 2.5 mg twice daily is an alternative option for extended phase therapy for risk reduction of VTE recurrence compared to apixaban 5 mg twice daily.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据